| NCT00550771 | Merck Sharp & Dohme LLC | Breast Neoplasm | 2007-07-16 | PHASE2 |
| NCT03949634 | Fudan University | Early Breast Cancer | 2017-09-01 | PHASE3 |
| NCT07109414 | Novita Pharmaceuticals, Inc.|Gynecologic Oncology Group | Platinum-resistant Ovarian Cancer | 2025-12-29 | PHASE2|PHASE3 |
| NCT02206425 | Oncotherapeutics|Takeda | Multiple Myeloma | 2014-09 | PHASE1|PHASE2 |
| NCT03596281 | Gustave Roussy, Cancer Campus, Grand Paris | Ovarian Cancer | 2018-12-05 | PHASE1 |
| NCT01004380 | Morphotek | Epithelial Ovarian Cancer | 2009-11 | PHASE1 |
| NCT03387943 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Poorly Differentiated Thyroid Carcinoma | 2017-03-06 | PHASE2 |
| NCT01837251 | AGO Research GmbH|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|ARCAGY+ GINECO GROUP|Australia New Zealand Gynaecological Oncology Group|Scottish Gynaecological Cancer Study Group | Recurrent Platinum-sensitive Ovarian Cancer | 2013-05 | PHASE3 |
| NCT03690739 | AGO Research GmbH | Recurrent Ovarian Carcinoma | 2019-08-09 | PHASE3 |
| NCT04101812 | Tianjin Medical University Second Hospital|CSPC Pharmaceutical Group Limited | Muscle Invasive Bladder Cancer | 2019-09-17 | PHASE2 |
| NCT02580058 | Pfizer | Ovarian Cancer | 2015-12-21 | PHASE3 |
| NCT00617591 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C. | Multiple Myeloma | 2008-01 | PHASE2 |
| NCT01991210 | Genentech, Inc. | Ovarian Cancer | 2014-02-06 | PHASE2 |
| NCT07286266 | GlaxoSmithKline|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Ovarian Neoplasms | 2026-06-24 | PHASE3 |
| NCT01329549 | Boehringer Ingelheim | Ovarian Neoplasms | 2011-04 | PHASE1 |
| NCT05868889 | Grupo Espa?ol de Investigación en Cáncer de Ovario | Ovarian Cancer | 2021-10-21 | |
| NCT06687070 | Ascentage Pharma Group Inc. | Platinum-resistant Recurrent Ovarian Cancer|Advanced Solid Tumor | 2024-12-17 | PHASE1 |
| NCT02272790 | AstraZeneca | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | 2015-01-30 | PHASE2 |
| NCT00722592 | Endocyte | Ovarian Cancer | 2008-09 | PHASE2 |
| NCT03446495 | Suriya Yessentayeva|Johnson & Johnson | Ovarian Cancer | 2017-03-28 | |
| NCT03268772 | Fudan University | Soft Tissue Sarcoma | 2015-04-01 | PHASE2 |
| NCT04244552 | Atreca, Inc. | Breast Cancer|Colorectal Cancer|Ovarian Cancer|Non-Small Cell Lung Cancer|Acral Lentiginous Melanoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|Esophageal Squamous Cell Carcinoma|Urothelial Carcinoma|DMMR Colorectal Cancer|MSI-H Colorectal Cancer|Melanoma|Platinum-Resistant Primary Peritoneal Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Epithelial Ovarian Cancer|Triple Negative Breast Cancer | 2020-02-11 | PHASE1 |
| NCT02098343 | Aprea Therapeutics | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | 2014-03 | PHASE1|PHASE2 |
| NCT04348032 | Chinese Academy of Medical Sciences|Jiangsu HengRui Medicine Co., Ltd. | Platinum-resistant Recurrent Ovarian Cancer | 2018-03-22 | PHASE2 |
| NCT04729387 | Novartis Pharmaceuticals | Ovarian Cancer | 2021-07-22 | PHASE3 |
| NCT03419494 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Adult Acute Lymphoblastic Leukemia | 2013-10-10 | |
| NCT01314105 | Boehringer Ingelheim | Ovarian Neoplasms|Peritoneal Neoplasms | 2011-03-15 | PHASE1 |
| NCT05346107 | Xijing Hospital | Breast Cancer|HER2-positive Breast Cancer | 2020-01-01 | PHASE2 |
| NCT04887961 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Relapsed Ovarian Cancer | 2020-10-01 | PHASE2 |
| NCT03598270 | Grupo Espa?ol de Investigación en Cáncer de Ovario|Hoffmann-La Roche|GlaxoSmithKline|AGO Study Group|Belgian Gynaecological Oncology Group|ARCAGY+ GINECO GROUP|Israeli Society of Gynecologic Oncology|MaNGO|Apices Soluciones S.L. | Recurrent Ovarian Carcinoma | 2018-11-21 | PHASE3 |
| NCT04274426 | AGO Research GmbH | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | 2021-10-13 | PHASE2 |
| NCT01541332 | Oncotherapeutics|Celgene Corporation | Multiple Myeloma | 2012-02 | PHASE1|PHASE2 |
| NCT06787612 | Regeneron Pharmaceuticals | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2025-05-28 | PHASE2 |
| NCT05536102 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 2022-09-05 | PHASE2 |
| NCT06619236 | Genmab | Platinum-resistant Ovarian Cancer | 2025-02-07 | PHASE3 |
| NCT05092360 | Mural Oncology, Inc|Merck Sharp & Dohme LLC | Platinum-resistant Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2022-01-10 | PHASE3 |
| NCT03907969 | AstraZeneca|Parexel | Advanced Malignancies | 2019-10-09 | PHASE1|PHASE2 |
| NCT05159193 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2021-12-20 | PHASE3 |
| NCT01666444 | Celgene|Gynecologic Oncology Group | Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2012-10-31 | PHASE2 |
| NCT05029999 | University of Texas Southwestern Medical Center|Celldex Therapeutics|Gateway for Cancer Research|National Institutes of Health (NIH) | HER2-negative Breast Cancer|Metastatic Breast Cancer | 2022-04-20 | PHASE1 |
| NCT00785798 | Yale University|Merck Sharp & Dohme LLC | Relapsed Lymphomas|Refractory Lymphomas | 2009-01 | PHASE1|PHASE2 |
| NCT01121406 | Boehringer Ingelheim | Ovarian Neoplasms | 2010-04 | PHASE2 |
| NCT07213804 | Eli Lilly and Company|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Asia-Pacific Gynecologic Oncology Trials Group | Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Neoplasm Metastasis | 2025-10-22 | PHASE3 |
| NCT01281254 | Amgen | Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer | 2011-04-18 | PHASE3 |
| NCT01051362 | The First Affiliated Hospital of Guangzhou Medical University | Non-small Cell Lung Cancer | 2006-02 | PHASE2 |
| NCT02421588 | PharmaMar | Ovarian Cancer | 2015-05 | PHASE3 |
| NCT02644278 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany | Advanced Solid Tumor | 2016-02-29 | PHASE1 |
| NCT03719326 | Arcus Biosciences, Inc.|Infinity Pharmaceuticals, Inc. | TNBC - Triple-Negative Breast Cancer|Ovarian Cancer | 2018-10-15 | PHASE1 |
| NCT03268382 | Aprea Therapeutics | High-grade Serous Ovarian Cancer | 2017-07-31 | PHASE2 |
| NCT03562533 | Konkuk University Medical Center|Seoul National University Hospital|National Cancer Center, Korea|Asan Medical Center|The Catholic University of Korea|Samsung Medical Center|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Ajou University|Severance Hospital | Ovarian Carcinoma | 2018-05-17 | |
| NCT02584478 | Advenchen Laboratories, LLC | Endometrial Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Cervical Carcinoma | 2015-12 | PHASE3 |
| NCT07218809 | AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation|Ventana Medical Systems, Inc | Epithelial Ovarian Cancer | 2025-12-29 | PHASE3 |
| NCT01388621 | WiSP Wissenschaftlicher Service Pharma GmbH|ClinAssess GmbH | Ovarian Cancer | 2011-10 | PHASE2 |
| NCT02866370 | NHS Greater Glasgow and Clyde|Boehringer Ingelheim|Cancer Research UK|European Organisation for Research and Treatment of Cancer - EORTC|Nordic Society of Gynaecological Oncology - Clinical Trials Unit|ARCAGY+ GINECO GROUP | Ovarian Clear Cell Carcinoma|Endometrial Clear Cell Carcinoma | 2015-04 | PHASE2 |
| NCT01246063 | Washington University School of Medicine | Multiple Myeloma | 2012-05-14 | PHASE1|PHASE2 |
| NCT06161025 | Daiichi Sankyo|Merck Sharp & Dohme LLC | Solid Cancer | 2024-02-27 | PHASE2|PHASE3 |
| NCT05613088 | Bristol-Myers Squibb|Eisai Inc. | Neoplasms, Ovarian | 2023-02-01 | PHASE2 |
| NCT01379989 | Mario Negri Institute for Pharmacological Research|PharmaMar|Averion International Corporation | Ovarian Cancer | 2011-06 | PHASE3 |
| NCT03639246 | Aravive, Inc. | Ovarian Cancer | 2018-12-06 | PHASE1 |
| NCT05261490 | Pfizer | Ovarian Cancer|Ovarian Neoplasms|Ovarian Carcinoma|Fallopian Tube Cancer|Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma | 2022-08-01 | PHASE1|PHASE2 |
| NCT03872947 | Toray Industries, Inc | Solid Tumor|Colorectal Cancer|Cholangiocarcinoma|Bladder Cancer|Ovarian Cancer|Gastric Cancer|Palpable Subcutaneous Malignant Lesions|Renal Cell Carcinoma|Melanoma|Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer | 2019-04-26 | PHASE1 |
| NCT05551507 | InxMed (Shanghai) Co., Ltd. | Platinum-resistant Ovarian Cancer | 2020-07-27 | PHASE1|PHASE2 |
| NCT02865811 | Dana-Farber Cancer Institute|Merck Sharp & Dohme LLC | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | 2016-09-15 | PHASE2 |